RAYMOND JAMES & ASSOCIATES - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 146 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$563,855
-12.2%
48,234
+1.0%
0.00%
-100.0%
Q2 2023$642,123
-30.4%
47,777
-14.2%
0.00%0.0%
Q1 2023$923,241
+17.3%
55,684
+31.6%
0.00%0.0%
Q4 2022$787,022
+109.9%
42,313
+44.9%
0.00%
Q3 2022$375,000
+140.4%
29,200
+30.8%
0.00%
Q2 2022$156,000
+300.0%
22,324
+90.4%
0.00%
Q4 2020$39,000
+11.4%
11,7260.0%0.00%
Q3 2020$35,000
-57.3%
11,726
-33.8%
0.00%
Q2 2020$82,000
+13.9%
17,726
-5.3%
0.00%
Q1 2020$72,000
-29.4%
18,726
-31.0%
0.00%
Q4 2019$102,000
-16.4%
27,133
+17.9%
0.00%
Q3 2019$122,000
+82.1%
23,007
+31.4%
0.00%
Q2 2019$67,000
+1.5%
17,507
+34.6%
0.00%
Q1 2019$66,000
+127.6%
13,007
-13.3%
0.00%
Q4 2018$29,000
-38.3%
15,007
+20.0%
0.00%
Q3 2018$47,00012,5070.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders